Search
nemolizumab (Mitchga)
Indications:
- treatment of prurigo nodularis
- treatment of moderate-severe atopic dermatitis
Adverse effects:
- serious treatment-emergent adverse events in < 3%
Mechanism of action:
- monoclonal antibody inhibiting IL-31 receptor alpha
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
dermatologic agent
References
- Silverberg JI, Wollenberg A, Reich A, et al.
Nemolizumab with concomitant topical therapy in adolescents and adults with
moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from
two replicate, double-blind, randomised controlled phase 3 trials.
Lancet. 2024 Jul 24:S0140-6736(24)01203-0
PMID: 39067461